Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Afatinib - Boehringer Ingelheim

Drug Profile

Afatinib - Boehringer Ingelheim

Alternative Names: Afatinib dimaleate; BIBW 2992 MA2; BIBW-2992; Gilotrif; Giotrif; Tomtovok; Tovok; Xovoltib

Latest Information Update: 20 Sep 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; European Organisation for Research and Treatment of Cancer; European Thoracic Oncology Platform; H. Lee Moffitt Cancer Center and Research Institute; Hanshin Oncology Group; Leiden University Medical Center; Okayama University; Translational Research In Oncology
  • Class Antineoplastics; Quinazolines; Radiation-sensitising agents; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer; CNS cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase III Breast cancer; Head and neck cancer
  • Phase II Chordoma; Gastric cancer; Glioma; Oesophageal cancer; Pancreatic cancer; Urogenital cancer
  • Phase I/II Rhabdomyosarcoma
  • Phase I Glioblastoma
  • No development reported Colorectal cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 02 Sep 2019 Boehringer Ingelheim completes the phase II LUX-Bladder 1 trial in Urogenital cancer (Monotherapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain, France and Italy (PO) (NCT02780687)
  • 29 Jul 2019 Boehringer Ingelheim completes a phase II trial in Gastric Cancer and Gastroesophageal cancer (First-line therapy, Inoperable/Unresectable, Late-stage disease, Combination therapy) in Greece (PO)(NCT01743365)
  • 06 Jun 2019 Boehringer Ingerheim and Okayama University terminate a phase II trial in Non-small cell lung cancer in Japan (UMIN000027432)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top